Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer

Oncology

Volumn 76, Issue 1, 2008, Pages 42-48

  Takahari, Daisuke ^a   Yamada, Yasuhide ^a   Okita, Natuko T ^a   Honda, Takuya ^a   Hirashima, Yoshinori ^a   Matsubara, Junichi ^a   Takashima, Atsuo ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Shirao, Kuniaki ^a   Shimada, Yasuhiro ^a   Shimoda, Tadakazu ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Insulin like growth factor 1 receptor

Indexed keywords

BIOLOGICAL MARKER; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SOMATOMEDIN C RECEPTOR; UFT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLON SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RECTAL NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 56449117907     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178164     Document Type: Article

References (30)

1. Editorial Board of Cancer Statistics in Japan: Cancer Statistics in Japan 2005 (in Japanese). Tokyo, Foundation for Promotion of Cancer Research, 2005.
2. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
3. Baselga J, Arteaga CL: Clinical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-2459.
4. Nielsen TO, Andrews HN, Cheang M, et al: Expression of the insulin-like growth factor-I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamysin. Cancer Res 2004;64:286-291.
5. Railo MJ, von Smitten K, Pekonen F: The prognostic value of insulin-like growth factor receptor-I in breast cancer patients: results of a follow-up study on 126 patients. Eur J Cancer 1994;30A:307-311.
6. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-230.
7. Hailey J, Maxwell E, Koukouras K, Bishop WR, Pachter JA, Wang Y: Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002;1:1349-1353.
8. Vallböhmer D, Iqbal S, Yang DY, et al: Molecular determinants of irinotecan efficacy. Int J Cancer 2006;119:2435-2442.
9. Takaoka M, Harada H, Andl CD, et al: Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004;64:7711-7723.
10. Caminard A, Lu Y, Pollak M: Co-targeting HER-2/ErbB2 and insulin-like growth factor-I receptors causes synergistic inhibition of growth on HER-2 overexpressing breast cancer cells. Med Sci Monit 2002;8:521-526.
11. Goetsch L, Gonzalez A, Leger O, et al: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005;113:316-328.
12. Cohen BD, Baker BA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-2073.
13. Higano C, Yu E, Whiting S, et al: A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol 2007, ASCO Annu Meet Proc 2007;25:3505.
14. Ryan CJ, Haqq CM, Simko J, et al: Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007;25:134-140.
15. de Alava E, Panizo A, Antonescu CR, et al: Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000;156:849-855.
16. Burrow S, Andrulis IL, Pollak M, Bell RS: Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-27.
17. Chng WJ, Gualberto A, Fonseca R: IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 2006;20:174-176.
18. Cunningham MP, Essapen S, Thomas H, et al: Coexpression of the IGF-1R, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006;28:329-335.
19. Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L, Sulkowski S: Expression of insulin-like growth factor-I receptor and proadoptotic Bax and Bak proteins in human colorectal cancer. Ann NY Acad Sci 2004;1030:377-383.
20. Peters G, Gongoll S, Langer C, et al: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 2003;443:139-145.
21. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer 2001;92:1331-1346.
22. McKay JA, Murray LJ, Curran S, et al: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumors and lymph node metastasis. Eur J Cancer 2002;38:2258-2264.
23. Spano JP, Lagorce C, Atlan D, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-108.
24. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004;351:2883.
25. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
26. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237.
27. Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F: Her-2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123.
28. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-207.
29. Adams TE, McKern NM, Ward CW: Signaling by the type I insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004;22:89-95.
30. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M: Insulin-like growth factor-I receptor signaling and resistance to Trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-1857.